P801: BASELINE AND EARLY POST-INFUSION BIOMARKERS ASSOCIATED WITH OPTIMAL RESPONSE TO IDECABTAGENE VICLEUCEL (IDE-CEL) IN THE KARMMA-3 STUDY OF TRIPLE-CLASS–EXPOSED RELAPSED AND REFRACTORY MULTIPLE MYELOMA
Julia Piasecki,
Keyur Desai,
Carolyn Courtney,
Ethan Thompson,
James Pratt,
Noopur Raje,
Krina Patel,
Marc S. Raab,
Mark Cook,
Katy Simonsen,
Mihaela Popa Mckiver,
Shari Kaiser,
Nathan Martin
Affiliations
Julia Piasecki
1 Bristol Myers Squibb, Seatle, United States
Keyur Desai
2 Bristol Myers Squibb, Princeton, United States
Carolyn Courtney
2 Bristol Myers Squibb, Princeton, United States
Ethan Thompson
1 Bristol Myers Squibb, Seatle, United States
James Pratt
2 Bristol Myers Squibb, Princeton, United States
Noopur Raje
3 Massachusetts General Hospital, Boston, United States
Krina Patel
4 MD Anderson Cancer Center, Houston, United States
Marc S. Raab
5 Heidelberg University Hospital, Heidelberg, Germany
